1.1001
-0.0349 (-3.07%)
-0.0349 (-3.07%)
Upgrade to Real-Time
Regular Market
Volume | 3,592 |
|
|||||
News | - | ||||||
Day High | 1.14 | Low High |
|||||
Day Low | 1.1001 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.14 | 1.1001 | 1.14 | 1.135 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
21 | 3,592 | $ 1.14 | $ 4,083 | - | 0.62 - 9.87 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:38:25 | 2 | $ 1.12 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 24.85M | 22.59M | 22.23M | $ 228.43k | $ - | -4.65 | 1.80 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 30.00k | 0.80% |
Sunshine Biopharma News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.28 | 1.30 | 1.08 | 1.22 | 277,320 | -0.1799 | -14.05% |
1 Month | 0.7965 | 1.30 | 0.7501 | 1.05 | 371,401 | 0.3036 | 38.12% |
3 Months | 0.9488 | 1.30 | 0.62 | 0.8930842 | 370,178 | 0.1513 | 15.95% |
6 Months | 1.33 | 1.50 | 0.62 | 0.9968055 | 435,317 | -0.2299 | -17.29% |
1 Year | 2.75 | 9.87 | 0.62 | 4.85 | 3,430,858 | -1.65 | -60.0% |
3 Years | 2.75 | 9.87 | 0.62 | 4.85 | 3,430,858 | -1.65 | -60.0% |
5 Years | 2.75 | 9.87 | 0.62 | 4.85 | 3,430,858 | -1.65 | -60.0% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |